Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics
暂无分享,去创建一个
Wei Yan | XieFeng Wang | Y. You | Yan-wei Liu | Wei Yan | Yanwei Liu | Yongping You | Rui Li | Xincheng Chen | Xiefeng Wang | Qi Hu | Rui Li | Xincheng Chen | Qi Hu | Xiefeng Wang | Q. Hu
[1] E. B. Jackson,et al. Effects of Colchicine and Radiation on Growth of Normal Tissues and Tumors , 1940 .
[2] A. Brandes,et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[5] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Philippe Chahinian. Epidemiology and Etiology , 2003 .
[7] Jan C Buckner,et al. Factors influencing survival in high-grade gliomas. , 2003, Seminars in oncology.
[8] Paola Pisani,et al. Genetic Pathways to Glioblastoma , 2004, Cancer Research.
[9] P. Kleihues,et al. Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.
[10] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[11] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] G. Dresemann. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Wen,et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas , 2006, Neurology.
[15] D. Bigner,et al. Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. McLendon,et al. Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.
[17] J. Buckner,et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.
[18] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[20] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[21] S. Pannullo,et al. Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas , 2008, Cancer.
[22] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. J. van den Bent,et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.
[24] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[25] B. O'neill,et al. Glioblastoma survival in the United States before and during the temozolomide era , 2012, Journal of Neuro-Oncology.
[26] Michael Weller,et al. Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.
[27] Alireza Khoshnevisan,et al. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care , 2013, Oncotarget.
[28] J. Akers,et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas , 2014, Genome research.
[29] T. Cloughesy,et al. Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.
[30] M. J. van den Bent,et al. Are we done with dose-intense temozolomide in recurrent glioblastoma? , 2014, Neuro-oncology.
[31] S. Fulda,et al. RIST: A potent new combination therapy for glioblastoma , 2015, International journal of cancer.